About Vela Pharmaceuticals
Vela Pharmaceuticals is a company based in Lawrenceville (United States) founded in 1998 was acquired by Pharmos in March 2006. Vela Pharmaceuticals has raised $41.3 million across 2 funding rounds from investors including J P Morgan, NEA and Venrock. Vela Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
- Headquarter Lawrenceville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$41.3 M (USD)
in 2 rounds
-
Latest Funding Round
$25 M (USD), Series D
Feb 19, 2002
-
Investors
J P Morgan
& 5 more
-
Employee Count
Not available
-
Acquired by
Pharmos
(Mar 14, 2006)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Vela Pharmaceuticals
Vela Pharmaceuticals has successfully raised a total of $41.3M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $25 million completed in February 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vela Pharmaceuticals
Vela Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include J P Morgan, NEA and Venrock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Seed capital is provided by Johnston Associates for healthcare startups.
|
Locked | Locked | Locked |
Investor details for Vela Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vela Pharmaceuticals
Investment portfolio details for Vela Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vela Pharmaceuticals
Detailed financials for Vela Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vela Pharmaceuticals Comparisons
Peer comparison for Vela Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vela Pharmaceuticals
Vela Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Therapies for central nervous system diseases and pain are developed.
|
|
| Locked | Locked | Locked |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| Locked | Locked | Locked |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
|
| Locked | Locked | Locked |
Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology.
|
|
| Locked | Locked | Locked |
Pasithea is focused on developing treatments for neurological disorders.
|
Detailed competitors of Vela Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vela Pharmaceuticals
Complete news archive for Vela Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vela Pharmaceuticals
Vela Pharmaceuticals was founded in 1998 and raised its 1st funding round 2 years after it was founded.
Vela Pharmaceuticals is headquartered in Lawrenceville, United States.
Vela Pharmaceuticals is a funded company, having raised a total of $41.3M across 2 funding rounds to date.
Vela Pharmaceuticals was a US-based, clinical stage pharma company developing therapeutics for nervous system disorders. In Oct.2006, it was acquired by Pharmos Corp. Vela develops therapeutics targeting neurotransmitters. At the time of acquisition, the company had a Phase 1b drug for the treatment of menopausal hot flashes; an asset in Phase 2 for the treatment of irritable bowel syndrome; and a late Phase 2 asset for the treatment of depression. The company was formerly known as Janus Pharmaceuticals.
Vela Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Vela Pharmaceuticals has 6 investors. Key investors include J P Morgan, NEA, Venrock, Johnston Associates, and MBF Capital Corporation.